They were able to show that CAF-derived HGF regulates liver tumor-initiating cells via activation of FRA1 in an Erk1/2-dependent manner, highlighting the possibility of targeting the CAF-derived, HGF-mediated c-Met/FRA1/HEY1 cascade as a therapeutic strategy for treatment of HCC. Here, HGF is linked to hepatocellular carcinoma.